These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27863353)

  • 1. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increment of HFABP Level in Coronary Artery In-Stent Restenosis Segments in Diabetic and Nondiabetic Minipigs: HFABP Overexpression Promotes Multiple Pathway-Related Inflammation, Growth and Migration in Human Vascular Smooth Muscle Cells.
    Chen K; Chen QJ; Wang LJ; Liu ZH; Zhang Q; Yang K; Wang HB; Yan XX; Zhu ZB; Du R; Zhang RY; Shen WF; Lu L
    J Vasc Res; 2016; 53(1-2):27-38. PubMed ID: 27372431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.
    Yang L; Zhu H; Sun Y; Yan P; Song X; Xu F; Yuan H; Chen L
    Clin Cardiol; 2022 Mar; 45(3):308-314. PubMed ID: 35032135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant in-stent restenosis in the drug eluting stent era.
    Theodoropoulos K; Mennuni MG; Dangas GD; Meelu OA; Bansilal S; Baber U; Sartori S; Kovacic JC; Moreno PR; Sharma SK; Mehran R; Kini AS
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):777-785. PubMed ID: 27184223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Chen T; Sun JL; Zhang J
    Coron Artery Dis; 2020 Nov; 31(7):586-589. PubMed ID: 32271235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
    Kastl SP; Katsaros KM; Krychtiuk KA; Jägersberger G; Kaun C; Huber K; Wojta J; Speidl WS
    PLoS One; 2020; 15(5):e0232483. PubMed ID: 32392256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum TREM-1 level is associated with in-stent restenosis, and activation of TREM-1 promotes inflammation, proliferation and migration in vascular smooth muscle cells.
    Wang F; Li C; Ding FH; Shen Y; Gao J; Liu ZH; Chen JW; Zhang RY; Shen WF; Wang XQ; Lu L
    Atherosclerosis; 2017 Dec; 267():10-18. PubMed ID: 29080545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.
    Lu L; Wang YN; Sun WH; Liu ZH; Zhang Q; Pu LJ; Yang K; Wang LJ; Zhu ZB; Meng H; Yang P; Du R; Chen QJ; Wang LS; Yu H; Shen WF
    Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):572-80. PubMed ID: 23372061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Redfors B; Généreux P; Witzenbichler B; Maehara A; Weisz G; McAndrew T; Mehran R; Kirtane AJ; Stone GW
    Am Heart J; 2018 Mar; 197():142-149. PubMed ID: 29447774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.